It has been suggested that the gut hormone cholecystokinin (CCK), by modulating insulin output from pancreatic p-cells, plays an important role in the enteroinsular axis. To investigate this hypothesis, eight rats were studied on two different occasions: after injection of L 364718, a specific antagonist of CCK binding to its membrane receptor, and after vehicle injection. In both studies a mixture of casein (11%) and glucose (9%) was infused through a chronic indwelling intraduodenal catheter to evoke CCK secretion. Plasma was analyzed for insulin, glucose, glucagon, and tyrosine many times during the procedure. Prior administration of the CCK antagonist significantly attenuated the increase in plasma insulin and glucagon after casein infusion. These results support the concept that cholecystokinin plays an important physiologic role in the in vivo regulation of postprandial plasma insulin and glucagon concentrations after protein ingestion. Diabetes 36:1212-15, 1987 I nsulin-mediated disposition of ingested nutrients is thought to be facilitated by the release of various gut factors (1,2). In this capacity these compounds, termed incretins (2), facilitate the release of insulin from the pancreatic 3-cell. Gastric inhibitory polypeptide (GIP) is a major factor involved in this enteroinsular axis (2-6). Recent studies, however, support the involvement of other factors as well (7). Our studies were conducted to determine the influence of cholecystokinin (CCK) on the plasma insulin response after intraduodenal nutrient infusion. Because of the diffi- culties associated with measuring low levels and multiple forms of CCK, we employed a potent and highly specific antagonist of CCK binding to its membrane receptor to block its in vivo actions (8). The results support the concept that CCK is an important in vivo incretin factor.
I
nsulin-mediated disposition of ingested nutrients is thought to be facilitated by the release of various gut factors (1, 2) . In this capacity these compounds, termed incretins (2) , facilitate the release of insulin from the pancreatic 3-cell. Gastric inhibitory polypeptide (GIP) is a major factor involved in this enteroinsular axis (2) (3) (4) (5) (6) . Recent studies, however, support the involvement of other factors as well (7) . Our studies were conducted to determine the influence of cholecystokinin (CCK) on the plasma insulin response after intraduodenal nutrient infusion. Because of the diffi-culties associated with measuring low levels and multiple forms of CCK, we employed a potent and highly specific antagonist of CCK binding to its membrane receptor to block its in vivo actions (8) . The results support the concept that CCK is an important in vivo incretin factor.
MATERIALS AND METHODS

ANIMALS
Male Sprague-Dawley rats (Charles River, Wilmington, MA), weighing 280-330 g were used. They were maintained on standard Ralston-Purina rat chow (Si Louis, MO) and were housed in an environmentally controlled room with a 12-h light/dark cycle. One week before the first study an internal jugular catheter, extending to the right atrium, and an intraduodenal catheter were implanted. The catheters were filled with heparin-povidone solution, sealed, and tunneled subcutaneously around the side of the neck to the back of the head. The catheters were externalized through an incision in the back of the neck. Only animals that were active and eating normally within 36 h after the surgery were used. All rats were fasted for 12 h before each study.
EXPERIMENTAL PROTOCOL Throughout the study the rats were allowed to move freely within the confines of a large cage, and the connecting tubing was suspended overhead by means of a pulley system. The venous catheter was used for blood withdrawal and infusion of the L 364718, and the intraduodenal catheter was used for infusion of a 9% glucose/11% casein solution (pH 7; Sigma, St. Louis, MO). The total volume of blood withdrawn was <2.5 ml/study; to avoid volume depletion and anemia, 1.5 ml of blood (diluted in 1.5 ml of heparinized saline) obtained by heart puncture from a littermate of the test animal was transfused through the venous catheter. Each rat was studied twice with a 5-to 7-day interim. Four animals underwent study 1 first, and four underwent study 2 first. Study 1. At 0900 h the heparin-povidone solution was aspirated from the jugular catheter, and a slow infusion (15 |xl/ min) of isotonic saline was initiated to preserve the catheter patency. Plasma samples for the determination of glucose and insulin concentrations were obtained at 15-min intervals from -6 0 to 0 min. Plasma samples for glucagon and tyrosine concentrations were obtained at -3 0 min. At -3 0 and 0 min, 1 mg/kg body wt i.v. of the CCK antagonist L 364718 (Merck, Sharp, and Dohme, West Point, PA) was administered in 0.05% methylcellulose vehicle. At 0 min a primed (2.27 ml/kg) continuous (0.16 ml/kg) intraduodenal infusion of a 9% glucose/11% casein solution was started and maintained throughout the 60 min study. Plasma samples for glucose and insulin determinations were obtained at 3-min intervals for the first 21 min of the infusion and at 10-min intervals thereafter. Plasma samples for tyrosine and glucagon concentrations were obtained at 30 and 60 min. Study 2. The experimental protocol was identical to study 1 except that at -3 0 and 0 min, a 0.05% methylcellulose vehicle injection was administered alone. In control studies, four rats underwent the same experimental protocol described in studies 1 and 2, but the intraduodenal infusion was represented by glucose alone. plasma insulin by radioimmunoassay with rat insulin (lot 615-D63-12-3, Lilly, Indianapolis, IN) as standard (9) . The insulin samples from any paired study (1 and 2) were processed in the same assay. The intra-assay C.V. was <9% and the interassay C.V. was <20%. Plasma tyrosine concentrations were determined by an automated ion-exchange chromatographic technique (Dionex D-500, Sunnyvale, CA) with an L-6 column and lithium citrate buffer. Plasma glucagon was determined with the COOH-terminal 30,000-M r antibody of Faloona and Unger (10) . CALCULATIONS Plasma insulin responses during the casein-glucose infusion represent the mean increment in plasma insulin concentration above baseline during the 0-to 60-min interval. The basal insulin concentration is derived from the mean of four determinations from -6 0 to 0 min. All data are presented as means ± SE. Statistical comparison between study 1 and study 2 have been performed by paired Student's t test.
ANALYTICAL PROCEDURES
RESULTS
Body weight, plasma glucose, and insulin concentrations. At the time of the study, body weight (302 ± 6 vs. 304 ± 7 g), fasting plasma glucose (118 ± 2 vs. 116 ± 2 mg/dl), and plasma insulin concentration (2.42 ± 0.10 vs. 2.40 ± 0.11 ng/ml) were similar in the rats injected with the vehicle or the CCK antagonist, respectively. Plasma glucose and insulin responses to casein/glucose intraduodenal infusion. After the intraduodenal infusion of 11 % casein/9% glucose in the control group, insulin secretion was stimulated, with a peak response at 15 min of 20.0 ± 3.5 ng/ml and a mean value of 10.6 ± 1.5 ng/ml over the last 40 min of the infusion (Fig. 1) . The administration of CCK inhibitor L 364718 at -3 0 and 0 min before the intraduodenal infusion significantly reduced the plasma insulin response; the peak value averaged 9.5 ± 1.6 ng/ml (P < .01) at 15 min, with a mean value of 5.8 ± 0.8 ng/ml ( P < .01) over the last 40 min of the infusion. The mean incremental insulin area (0-60 min) in the L 364718-treated group was also significantly reduced, i.e., 229 ± 49 vs. 512 ± 69 ng/ml (P < .01). The plasma glucose incremental area (0-60 min) was 1916 ± 290 mg/dl in the vehicle-injected rats and 2454 ± 237 mg/dl in the CCK-antagonistinjected rats. After a primed (2.20 mg/kg body wt) continuous (15 mg • kg~1 • min~1) infusion of glucose alone, both the plasma glucose incremental areas (0-60 min; 3673 ± 378 vs. 3241 ± 391 mg/dl) and the plasma insulin incremental areas (0-60 min; 258 ± 71 vs. 273 ± 63 ng/ml) were similar in the vehicle-injected group and in the L 364718-injected groups. Plasma glucagon and tyrosine concentrations. The basal plasma glucagon concentration was 139 ± 4 and 148 ± 12 pg/ml in the control and L 364718-treated rats, respectively (Fig. 2) . In both experimental protocols, a significant increase in plasma glucagon concentration was observed at 30 and 60 min after the casein infusion. However, the magnitude of this increment was significantly reduced in the rats treated with L 364718 (190 ± 17 vs. 254 ± 3 pg/ml at 30 min and 211 ± 8 vs. 244 ± 7 pg/ml at 60 min, P < .01) in the treated and nontreated animals, respectively. Plasma tyrosine concentrations were similar in the two protocols at 0 min (65 ± 2 vs. 62 ± 5 |xM) and 30 min (128 ± 5 vs. 110 ± 8 (iM); a barely significant difference was detected at 60 min (215 ± 19 vs. 165 ± 5 |xM, P < .05).
DISCUSSION
CCK is a potent glucose-dependent stimulus for insulin secretion in the perfused rat pancreas and in isolated rat islets (11) (12) (13) . Our findings suggest that it plays a similar role in vivo. In the experiments reported here, a newly developed and highly specific antagonist of CCK, the benzodiazepine derivative L 364718, was employed. Our previous results with this compound in isolated perifused islets have demonstrated that at low doses (1 nM), it reduces CCK-8S-induced insulin output (in the presence of 7 mM glucose) (14) ; however, even at excessive levels (1 JJLM) it has no adverse impact on glucose-, glyceraldehyde-, or a-ketoisocaproateinduced insulin release. Previous studies with other CCKsensitive tissues have demonstrated a similar remarkable degree of inhibitory selectivity (8) .
By studying chronically catheterized rates in randomized order on two occasions, we have been able to detect dramatic effects of this inhibitor on insulin release. The rise in plasma insulin concentrations, in response to a primed continuous intraduodenal infusion of casein (11%) and glucose (9%) mixture, was significantly reduced by prior exposure of the B-cells to L 364718. Incremental areas were less than half of the level reached in the same rats in the absence of the antagonist (229 ± 49 vs. 512 ± 69 ng/ml). Note that the insulin concentrations observed here in the presence of the inhibitor approximate the levels we have previously observed after intraduodenal infusion of glucose alone (15) . In control studies in which glucose alone was infused intraduodenally in two instances, in the presence or absence of the specific CCK antagonist L 364718, the incremental insulin areas were similar in the presence (273 ± 63 ng/ml) and absence (258 ± 71 ng/ml) of the CCK antagonist and closely approximate the values obtained in study 1 (229 ± 49 ng/ml). Consistent with the finding that protein, but not glucose, is an effective stimulant of CCK secretion (16), the caseininduced increment in insulin output above that noted to glucose alone was virtually abolished by L 364718. Because the effect of casein on insulin release is probably mediated by its positive impact on CCK output from duodenal cells (16) , the physiologic role of CCK in postprandial elevations in insulin levels due to protein ingestion in rats is emphasized.
The small difference in the glucose profile after the administration of equal amounts of casein/glucose solution in the two experimental protocols is clearly disproportionate to the relevant impairment in the insulin response and deserves comment. A marked degree of hyperglycemia after L 364718, an effect due to diminished circulating levels of insulin, might have been anticipated. This was, however, not observed. Because CCK is also known to increase glucagon output from the a-cells (17) , the contribution of glucagon to this situation was considered. Our results demonstrate that casein administration increases glucagon output from acells and that this effect is reduced by the CCK antagonist. The hyperglycemic effect of hypoinsulinemia in response to L 364718 administration may be largely counteracted by the hypoglycemic effect of hypoglucagonemia.
Because tyrosine is the most representative amino acid in casein, we monitored protein absorption by measuring the levels of tyrosine in plasma. No significant differences were detected at 0 or 30 min from the beginning of the intraduodenal infusion of casein and glucose. The reduction of tyrosine concentrations in the L 364718-treated rats at 60 min confirms the inhibitory action of the blocker on exocrine pancreas as well. However, it is unlikety that fluctuations in amino acid levels contributed significantly to the differences in insulin and glucagon responses. The fact that insulin and glucagon levels were significantly reduced when amino acid levels were similar in both groups argues against a major role for amino acids in observed differences in pancreatic hormone secretion.
